普米克令舒、沐舒坦、庆大霉素氧气驱动雾化吸入防治早产儿肺透明膜病46例临床分析

Clinical analysis of 46 case of treating premature infants with hyaline membrane lung disease by using pulmicort,ambroxol and gentamycin associated with aerosol inhalation driven by oxygen

目的观察普米克令舒,沐舒坦,庆大霉素联合氧气驱动雾化吸入防治早产儿肺透明膜病的疗效。方法分治疗组与对照组,治疗组为我院2005年6月至2009年6月收治的胎龄29～35周的早产儿46例在生后4h内使用普米克令舒,沐舒坦,庆大霉素联合氧气驱动雾化吸入,对照组为2003年1月至2005年6月我院收治的未使用雾化吸入的条件相同的早产儿45例。结果治疗组46例出现肺透明膜病2例,对照组45例出现肺透明膜病8例。结论普米克,沐舒坦,庆大霉素联合防治早产儿肺透明膜病疗效满意,方法简便,值得在基层医院推广。

Objective To observe the effect of treating premature infants with hyaline membrane lung disease by using Pulmicort,Ambroxol and gentamycin associated with aerosol inhalation driven by oxygen.Methods Premature infants ranging from 29 to 35 weeks were divided into two groups.46infants of the treatment group,who were in hospital from June 2005 to June 2009,were given pulmicort,ambroxol and gentamycin associated with aerosol inhalation driven by oxygen in four hours after they were born.45 infants of the control group,who were in hospital from January 2003 to June 2005,had the same condition comparing with the treatment group except pulmicort,ambroxol and gentamycin associated with aerosol inhalation driven by oxygen.Results There were two children having the hyaline membrane lung disease in treatment group,on the other hand,there were eight children having the same disease in the control group.Conclusion Treating premature infants with hyaline membrane lung disease by using pulmicort,ambroxol and gentamycin associated with aerosol inhalation driven by oxygen.received satisfactory therapeutic effects and it＇s convenient and worth promoting it in the primary hospital